UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 1, 2023
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | ☒ | Form 40-F | ☐ |
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 1, 2023, Immatics N.V. (“Immatics”) issued a press release announcing that Bristol Myers Squibb exercised its option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors. Immatics will receive an option payment of $15 million and is eligible for up to $490 million in milestone payments in addition to tiered royalties based on net sales of the product.
EXHIBIT INDEX
Exhibit No. | Description |
99.1 | Press release dated May 1, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
IMMATICS N.V. | ||
Date: May 1, 2023 | ||
By: | /s/ Harpreet Singh | |
Name: | Harpreet Singh | |
Title: | Chief Executive Officer |